Menu

HomeConferencesCollectionsCalls for PapersMSF Research EthicsClinical Case ReportingAboutMy Saved Content
Logo

Science Portal

  • My Saved Content
  • Browse All
  • Conferences
  • Collections
  • Calls for Papers
  • MSF Research Ethics
  • Clinical Case Reporting
  • About
English
logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.6224.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Export All Citations
Copyright © Médecins Sans Frontières
v2.1.6224.produseast1
Homepage featured | Collections | MSF Science Portal
Homepage featured

Homepage featured

Collection Content

Download Citations
  • Download citations in various formats (CSV, BibTeX, EndNote) for use in reference managers and bibliographies.

  • All Assets (6)
  • CSV
  • BibTeX
  • EndNote
Download Citations
  • Download citations in various formats (CSV, BibTeX, EndNote) for use in reference managers and bibliographies.

  • All Assets (6)
  • CSV
  • BibTeX
  • EndNote

See more collections

TB-PRACTECAL Trial—Evidence for a shorter, safer, more effective treatment for drug-resistant tuberculosis

TB-PRACTECAL Trial—Evidence for a shorter, safer, more effect...
Drug-resistant tuberculosis (DR-TB) remains an especially deadly form of the ancient scourge of TB, while current treatments are long, toxic, and ineffective for half of all patients. Aiming to change this unacceptable status quo, in the mid-2010’s MSF and partners launched three clinical trials to test novel regimens containing the first new TB drugs in decades. On 22 December 2022 the New England Journal of Medicine published findings from TB-PRACTECAL, a three-country randomized controlled trial, showing that a shorter regimen is safer and cured 89% of DR-TB patients, compared with 52% on the standard of care. These findings have already been incorporated into the World Health Organization’s new TB treatment guidelines. A separate study shows that the new regimen is also more cost-effective. Alongside these results the content collection linked below highlights other aspects of the trial, from community engagement strategies that helped shape TB-PRACTECAL to setbacks arising from the Covid-19 pandemic. It also examines urgent challenges in scaling up access to these life-saving drugs, including affordability and patent barriers.
Medical and humanitarian harms of restrictive European migration policies

Medical and humanitarian harms of restrictive European migrat...
Neglected tropical diseases

Neglected tropical diseases
View All Collections
Conflict, persecution, poverty, food insecurity and natural disasters—increasingly fueled by climate change—continue to drive migration globally. Yet many wealthy countries are doubling down on hostile policies to prevent people from seeking safety within their borders, thereby subjecting them to a wide range of harms. In a newly-published report MSF focuses on European Union and member state policies that intensify exposure to violence, exploitation, risk of drowning at sea, disease, and lack of access to basic health care and shelter, both within European Union borders and beyond. The Collection linked below presents this report alongside selected publications illustrating the broader context, based on quantitative studies and accounts from MSF patients and medical teams over nearly a decade of operational experience along the European migration route. From violent, squalid detention centers in Libya— where people intercepted by the EU-supported Libyan coast guard are forcibly returned —to perilous Mediterranean crossings in flimsy rubber boats and often abysmal reception centers and camps within the EU, it documents how these policies and practices further harm highly vulnerable people seeking safety and protection.

Each year hundreds of thousands of people die from a neglected tropical disease, while many more suffer serious illness or lifelong disability. Yet as we mark World Neglected Tropical Diseases (NTD) Day on 30th January, global progress towards eliminating these diseases is threatened by shifting global health priorities and declining investment in the wake of the Covid-19 pandemic.


The content collection linked below offers a snapshot of MSF’s work on managing some of the most deadly NTDs, finding better tools and models of care for highly affected populations, and advocating for greater access to care and increased global funding. Several authors describe our programs and lessons learned from a decade of treating snakebite victims in sub-Saharan Africa. Two studies evaluate shorter, less toxic treatment for visceral leischmaniasis, while a policy analysis proposes critical steps towards eliminating this horrific disease in East Africa. Last, reports from Sokoto, Nigeria describe the collaborative development of a comprehensive model of care for noma.

Journal Article
|
Research

Post-surgical scar management and rehabilitation in burn patients: Insights from Gaza’s challenging context - A retrospective descriptive study

Qaradaya AEH, Van Hulse J, Younis J, Swairjo F, Al Far H,  et al.
2026-07-07 • PLOS Global Public Health
2026-07-07 • PLOS Global Public Health

Burn injuries represent a challenge in the Gaza Strip, where access to rehabilitation services is constrained by ongoing conflict and limited healthcare resources. This study describe...

Journal Article
|
Case Report/Series

First culture-confirmed melioidosis case in Mozambique: A wakeup call for better diagnostics and clinical awareness

Cruz SC, Raimundo C, Andela L, Marcos J, Joao N,  et al.
2026-05-10 • Oxford Medical Case Reports
2026-05-10 • Oxford Medical Case Reports

Melioidosis is a disease caused by Burkholderia pseudomallei and is an underrecognised cause of severe infection in sub-Saharan Africa. In Mozambique, where infectious diseas...

Journal Article
|
Research

Shotgun metagenomic analysis of the oral microbiomes of children with noma

Olaleye M, O’Ferrall AM, Goodman RN, Kabila DW, Peters M,  et al.
2026-03-20 • PLOS Neglected Tropical Diseases
2026-03-20 • PLOS Neglected Tropical Diseases

Noma is a rapidly progressive orofacial gangrene that predominantly affects children living in extreme poverty. Despite its documentation since antiquity and its designation as a Worl...

Journal Article
|
Letter

The effects of armed conflict on children and adolescents: Policy statement

Umphrey L, Patel A, Alayyan A, Haq HA, Suchdev PS,  et al.
2026-02-17 • Pediatrics
2026-02-17 • Pediatrics
Journal Article
|
Research

Risk stratification of childhood infection using host markers of immune and endothelial activation in Asia (Spot Sepsis): a multi-country, prospective, cohort study

Chandna A, Koshiaris C, Mahajan R, Ahmad RA, Van Anh DT,  et al.
2025-09-01 • Lancet Child and Adolescent Health
2025-09-01 • Lancet Child and Adolescent Health

BACKGROUND

Prognostic tools for febrile illnesses are urgently required in resource-constrained community contexts. Circulating immune and endothelial activatio...

Journal Article
|
Short Report

Providing emergency medical care at the Belarus-Poland border

Zadykowicz R, Kuc J, Ladomirska J, Zamatto F, Lim SY
2025-05-01 • Forced Migration Review
2025-05-01 • Forced Migration Review